Myeloproliferative Neoplasm, BCR-ABL1 Negative

Myeloproliferative Neoplasm, BCR-ABL1 Negative — Trials · CancerIndex

Clinical trials

Registered studies

333 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 94
Recruiting: 50
Ph III recruiting: 7
Growth YoY: —
Industry share: 41%
Top sponsor: City of Hope Medical Center
Termination share: 35.2%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (56)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05269771	MAP to Provide Access to Ruxolitinib, for Patients With Polycythemia Vera	no longer available	—	—	Novartis PharmaceuticalsINDUSTRY	8	Nov 5, 2025	clinicaltrials
NCT03592576	Expanded Access to Navitoclax	no longer available	—	—	AbbVieINDUSTRY	0	May 6, 2024	clinicaltrials